Beijing Huonland Pharmaceutical

Beijing Huonland Pharmaceutical is a clinical-stage Chinese biotechnology company specializing in the development of innovative biologics and gene therapies for cardiovascular and ophthalmic diseases. The company's lead candidate, NL003, is a plasmid-based Hepatocyte Growth Factor (HGF) gene therapy currently in Phase 3 clinical trials for the treatment of critical limb ischemia (CLI). Huonland's R&D focus extends to therapeutic angiogenesis and the development of recombinant proteins to address significant unmet medical needs in chronic wound healing and vascular disorders. With a robust manufacturing infrastructure and a dedicated research center in Beijing, the company is positioned as a leader in the domestic gene therapy landscape.